Benralizumab (Fasenra): A Comprehensive Monograph on its Pharmacology, Clinical Efficacy, and Therapeutic Role in Eosinophil-Driven Disease

1.0 Executive Summary & Introduction

Benralizumab, marketed under the brand name Fasenra, represents a significant advancement in the targeted biological therapy of diseases driven by eosinophilic inflammation.[1] It is a humanized, afucosylated IgG1 kappa (IgG1k) monoclonal antibody engineered to act as a potent interleukin-5 receptor alpha (IL-5Rα)-directed cytolytic agent.[2] This mechanism distinguishes it from other biologics in its class, which typically target the IL-5 ligand rather than its receptor, affording Benralizumab a unique pharmacological profile characterized by rapid and profound eosinophil depletion.[4]

Developed by MedImmune and currently marketed by AstraZeneca, Benralizumab has secured regulatory approval in numerous jurisdictions, including the United States and the European Union, for two primary indications: as an add-on maintenance treatment for severe eosinophilic asthma (SEA) in adults and children, and for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).[6] Its clinical development has been underpinned by robust Phase III trials demonstrating significant reductions in exacerbation rates, improvements in lung function, and a substantial oral corticosteroid-sparing effect.[8]

The therapeutic action of Benralizumab is multifaceted, involving both the blockade of IL-5-mediated pro-survival signaling and, more critically, the induction of eosinophil apoptosis through enhanced antibody-dependent cell-mediated cytotoxicity (ADCC).[2] This dual-action mechanism is augmented by novel, recently elucidated pathways including antibody-dependent cellular phagocytosis (ADCP) and macrophage-amplified apoptosis, further contributing to its potent anti-eosinophilic activity.[11]

Beyond its approved uses, Benralizumab has been extensively investigated as a therapeutic agent and a biological probe in other eosinophilic disorders. Its study in hypereosinophilic syndrome (HES) has shown promising long-term efficacy and safety, leading to ongoing Phase III investigations.[13] Conversely, its evaluation in eosinophilic esophagitis (EoE) in the MESSINA trial, while demonstrating profound histologic eosinophil clearance, failed to produce a corresponding improvement in clinical symptoms of dysphagia.[15] This pivotal finding has not only halted its development for EoE but has also provided invaluable insights into the complex pathophysiology of the disease, suggesting that eosinophils may not be the sole drivers of symptoms in established cases.

This monograph provides an exhaustive analysis of Benralizumab, synthesizing data from technical specifications, regulatory filings, peer-reviewed literature, and clinical trial results. It will detail the drug's physicochemical properties, provide a multi-layered exploration of its mechanism of action, review its pharmacokinetics and pharmacodynamics, critically evaluate its clinical efficacy and safety, and place it in the context of the broader therapeutic landscape for Type 2 inflammatory diseases.

2.0 Drug Profile and Physicochemical Characteristics

The precise characterization of a biologic agent is fundamental to understanding its function and clinical application. Benralizumab is a well-defined monoclonal antibody with specific structural and chemical properties that underpin its therapeutic activity.

2.1 Nomenclature and Identifiers

Benralizumab is identified globally through a standardized set of names and codes that ensure clarity in clinical, research, and regulatory contexts.

• Generic Name: Benralizumab [1]
• Pronunciation: ben" ra liz' ue mab [1]
• Brand Name: Fasenra [1]
• Aliases/Development Codes: The drug was known by several codes during its development phase, most notably MEDI-563 and BIW-8405.[3]
• DrugBank ID: DB12023 [1]
• CAS Number: 1044511-01-4 [1]
• UNII (Unique Ingredient Identifier): 71492GE1FX [1]
• ATC (Anatomical Therapeutic Chemical) Code: R03DX10, classifying it as an "Other drug for obstructive airway diseases, inhalant".[1]

2.2 Structural and Chemical Properties

Benralizumab is a complex protein therapeutic with defined molecular characteristics.

• Type: It is a biotech product, specifically a monoclonal antibody (mAb).[1] It is classified as a humanized IgG1 kappa (IgG1k) immunoglobulin, which was originally developed from a murine (mouse) antibody source and subsequently modified to increase its similarity to human antibodies, thereby reducing immunogenicity.[1]
• Molecular Formula: The empirical formula for the protein is C6492​H10060​N1724​O2028​S42​.[1]
• Molecular Weight / Molar Mass: As is common with large glycoproteins, slight variations in the reported molecular weight exist across different analytical methods and databases. Reported values include 146056.45 g·mol−1 [1], 146054.0 Da [2], 146.06 kDa [17], and 145.5 kDa.[3] These values are all within a narrow range and reflect the consensus molecular mass of the antibody.
• Formulation: Benralizumab is supplied as a sterile, preservative-free solution for subcutaneous injection. The solution is described as clear to opalescent and colorless to slightly yellow. It may contain a few translucent or white to off-white proteinaceous particles, which is considered normal for this type of product.[21] A specific formulation described in technical literature consists of 100 mM Pro-Ac and 20mM Arg at a pH of 5.0.[3]

Table 1: Key Physicochemical and Pharmacological Properties of Benralizumab

Property	Description/Value	Source(s)
Generic Name	Benralizumab	1
Brand Name	Fasenra	1
DrugBank ID	DB12023	1
CAS Number	1044511-01-4	1
Drug Class	Biotech, Monoclonal Antibody, Interleukin Inhibitor	1
Type	Humanized IgG1k Monoclonal Antibody	2
Target	Interleukin-5 Receptor Subunit Alpha (IL-5Rα, CD125)	1
Molecular Formula	C6492​H10060​N1724​O2028​S42​	1
Average Molecular Weight	~146 kDa	1
Route of Administration	Subcutaneous	1
ATC Code	R03DX10	1

3.0 Comprehensive Mechanism of Action (MoA)

The therapeutic efficacy of Benralizumab is rooted in its sophisticated and multi-faceted mechanism of action, which targets a central pathway in Type 2 inflammatory diseases. Its unique design allows for a more direct and potent effect on eosinophils compared to other biologics in its class.

3.1 The Pathophysiological Role of the IL-5/IL-5R Axis in Type 2 Inflammation

To appreciate Benralizumab's mechanism, it is essential to first understand its target's role in disease. Interleukin-5 (IL-5) is a homodimeric cytokine that serves as the principal driver of eosinophil biology.[5] Produced mainly by T helper 2 (Th2) lymphocytes and group 2 innate lymphoid cells (ILC2s), IL-5 orchestrates the entire lifecycle of eosinophils, including their growth, differentiation from hematopoietic precursors in the bone marrow, recruitment to tissues, subsequent activation, and prolonged survival by inhibiting apoptosis.[4]

The biological effects of IL-5 are mediated through its interaction with the IL-5 receptor (IL-5R), which is expressed on the surface of eosinophils and basophils.[5] The IL-5R is composed of two subunits: a ligand-specific alpha subunit (IL-5Rα, also known as CD125) and a beta common (βc) subunit that is shared with the receptors for IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF).[5] The high-affinity binding of IL-5 to the IL-5Rα subunit initiates a critical conformational change, promoting the heterodimerization of the α and βc subunits. This dimerization event triggers the activation of intracellular signaling cascades, prominently featuring the Janus kinase/Signal Transducer and Activator of Transcription (JAK/STAT) pathway (specifically JAK2 and STAT1, 3, and 5), as well as the Mitogen-Activated Protein Kinase (MAPK) and Phosphoinositide 3-Kinase (PI3K) pathways.[5]

The culmination of this signaling is the expression of genes that drive the hallmark features of eosinophilic inflammation. In diseases like severe asthma, this manifests as a "T2-high" inflammatory phenotype, characterized by eosinophilia in the blood and airways, airway hyperresponsiveness, mucus hypersecretion, and tissue remodeling, all of which contribute to clinical symptoms and disease progression.[2]

3.2 Dual-Action Eosinophil Depletion: A Mechanistic Deep Dive

Benralizumab employs a unique, dual-action strategy to neutralize the effects of the IL-5/IL-5R axis, resulting in profound and rapid eosinophil depletion. This contrasts sharply with other anti-eosinophilic biologics that act solely by sequestering the IL-5 ligand.

3.2.1 Inhibition of IL-5-Mediated Signal Transduction

The first component of Benralizumab's action is direct receptor antagonism. The antibody's antigen-binding fragments (Fab) bind with very high affinity to Domain I of the IL-5Rα subunit.[2] The dissociation constants (

KD​) reported are in the picomolar range, indicating a very tight and stable interaction, with values of 11 pM for human IL-5Rα and 42 pM for cynomolgus monkey IL-5Rα.[20] The binding site for Benralizumab on IL-5Rα is located in close proximity to the binding site for the IL-5 ligand itself.[5] Consequently, when Benralizumab is bound to the receptor, it sterically hinders IL-5 from docking. This blockade effectively prevents ligand-induced receptor activation, the heterodimerization of the α and βc subunits, and the initiation of the downstream pro-survival signaling cascades. By cutting off this vital survival signal, Benralizumab promotes the natural process of eosinophil apoptosis.[2]

3.2.2 Enhanced Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)

The second, and arguably more defining, mechanism of Benralizumab is its ability to actively recruit the body's own cytotoxic cells to eliminate eosinophils. In addition to its Fab-mediated receptor blocking, the constant region (Fc) of the Benralizumab antibody is engineered to bind to the Fc gamma receptor IIIa (FcγRIIIa, or CD16a).[2] This receptor is expressed on the surface of potent immune effector cells, most notably Natural Killer (NK) cells, but also on macrophages and neutrophils.[2]

When Benralizumab simultaneously binds to IL-5Rα on an eosinophil and FcγRIIIa on an NK cell, it forms a molecular bridge, creating a "cytotoxic synapse" between the two cells.[11] This cross-linking event activates the NK cell, triggering it to degranulate and release its cytotoxic payload—including proteins like perforin and granzymes—directly onto the surface of the targeted eosinophil. These lytic proteins induce rapid and efficient apoptosis of the eosinophil.[10] This ADCC mechanism is exceptionally potent, with half-maximal effective concentrations (

EC50​) in the low picomolar range: 0.9 pM for human eosinophils and 0.5 pM for basophils.[17] This active killing mechanism, rather than passive blockade, is a key reason for the rapid and near-complete depletion of eosinophils observed clinically within just 24 hours of administration.[4]

3.3 The Structural Basis for Potency: The Role of Afucosylation in FcγRIIIa Binding

The extraordinary potency of Benralizumab's ADCC activity is not accidental; it is the result of deliberate molecular engineering. Benralizumab is an "afucosylated" antibody, meaning that during its manufacturing process in Chinese Hamster Ovary (CHO) cells, the fucose sugar residue that is normally present in the N-linked oligosaccharide core of the antibody's CH2 domain is omitted.[2]

This seemingly minor structural modification has a profound functional consequence. The absence of fucose dramatically alters the conformation of the Fc region, resulting in a 5- to 50-fold increase in its binding affinity for the FcγRIIIa receptor on NK cells.[5] This significantly enhanced affinity is the direct driver of the magnified and highly efficient ADCC response. It ensures that even at low concentrations, Benralizumab can effectively engage NK cells and direct them to kill target eosinophils, explaining its ability to achieve rapid, deep, and sustained eosinophil depletion.[11]

3.4 Emerging Mechanisms: Antibody-Dependent Cellular Phagocytosis (ADCP) and Macrophage-Amplified Apoptosis

Recent advanced research using co-culture assays and real-time imaging has uncovered additional, complementary mechanisms that contribute to Benralizumab's overall anti-eosinophilic effect, adding further layers to its mode of action.[11]

First, Benralizumab has been shown to mediate eosinophil phagocytosis by macrophages, a process known as antibody-dependent cellular phagocytosis (ADCP). Similar to ADCC, this involves the antibody acting as a bridge, in this case between an eosinophil and a macrophage. Live-cell imaging has visualized the stepwise process: the establishment of a macrophage-eosinophil immune synapse, the formation of a phagocytic cup by the macrophage, and the subsequent engulfment and destruction of the opsonized eosinophil.[11]

Second, a novel amplification loop involving macrophages and NK cells has been identified. The process begins with NK cells being activated by Benralizumab-mediated interactions. These activated NK cells then secrete interferon-gamma (IFN-γ). IFN-γ, in turn, acts on macrophages, stimulating them to produce and secrete Tumor Necrosis Factor (TNF). This macrophage-derived TNF then acts as a secondary cytotoxic signal, binding to TNF Receptor 1 (TNFR1) expressed on the surface of eosinophils. This engagement further enhances eosinophil apoptosis through the upregulation of cytochrome c and increased caspase-3/7 activity, effectively amplifying the initial killing signal from the NK cells.[11]

These emerging mechanisms illustrate a complex interplay between different arms of the innate immune system, all orchestrated by Benralizumab to ensure the comprehensive removal of pathogenic eosinophils.

It is noteworthy that official product websites and prescribing information sometimes state that "The mechanism of action of benralizumab in asthma has not been definitively established".[24] This statement can appear contradictory to the extensive and detailed body of scientific evidence. This discrepancy arises not from a lack of scientific understanding of the drug's biological and pharmacological actions, but from the high threshold of regulatory language. While the molecular interactions, the role of afucosylation, and the resulting cellular events like ADCC are well-characterized, the term "definitively established" in a regulatory context implies a formalized, quantitative link between each specific mechanistic component and a precise percentage of the final clinical outcome observed in pivotal trials (e.g., a 51% reduction in exacerbations). The biological actions are known in detail, but this final, quantitative attribution for regulatory purposes remains formally qualified.

4.0 Clinical Pharmacology: Pharmacodynamics and Pharmacokinetics

The clinical pharmacology of Benralizumab describes the relationship between drug concentrations and its effects on the body (pharmacodynamics) as well as how the body processes the drug (pharmacokinetics). These properties are crucial for determining the appropriate dosing regimen and understanding its clinical profile.

4.1 Pharmacodynamic Profile

The pharmacodynamic effects of Benralizumab are a direct consequence of its potent mechanism of action and are primarily characterized by the depletion of its target cells.

• Eosinophil Depletion: The hallmark effect of Benralizumab is the rapid, profound, and sustained depletion of eosinophils. Following subcutaneous administration, a near-complete reduction in blood eosinophil counts (median absolute count of 0 cells/μL) is observed within 24 hours of the first dose.[4] This effect is maintained throughout the entire treatment period with both 4-week and 8-week dosing regimens.[4]
• Tissue-Level Effects: The depletion is not limited to the circulation. Studies have demonstrated significant reductions of eosinophils in various tissues. In patients with asthma, a median reduction of 96% in airway mucosa eosinophils was observed, compared to a 47% reduction with placebo.[4] Similar depletion has been noted in sputum and in the bone marrow, where it specifically affects eosinophil precursors without impacting other cell lineages.[2]
• Basophil Depletion: Basophils also express the IL-5Rα subunit and are therefore also targeted by Benralizumab. Clinical trials have confirmed a reduction in blood basophil numbers following treatment.[4]
• Biomarker Reduction: Consistent with the depletion of eosinophils, serum levels of eosinophil-derived granular proteins, such as eosinophil-derived neurotoxin (EDN) and eosinophil cationic protein (ECP), are also significantly reduced.[4]

4.2 Pharmacokinetic (PK) Profile

The pharmacokinetics of Benralizumab are described as linear and dose-proportional, based on population pharmacokinetic analyses from clinical trials.[2]

• Absorption: After subcutaneous administration, Benralizumab is absorbed relatively slowly, with an absorption half-life of approximately 3.5 days. The estimated absolute bioavailability is approximately 59%. There are no clinically meaningful differences in bioavailability when the injection is administered to the abdomen, thigh, or upper arm.[23]
• Distribution: Benralizumab has a limited volume of distribution, suggesting it is primarily confined to the vascular and interstitial spaces, with minimal distribution into deep tissues. For a typical 70 kg individual, the central volume of distribution is estimated to be 3.1 L, and the peripheral volume of distribution is 2.5 L.[23]
• Metabolism (Biotransformation): As a large protein, Benralizumab is not metabolized by hepatic cytochrome P450 enzymes. Instead, like other endogenous IgG antibodies, it is expected to be degraded into small peptides and amino acids by proteolytic enzymes that are widely distributed throughout the body.[2]
• Elimination: Benralizumab exhibits linear pharmacokinetics, and there is no evidence of target receptor-mediated clearance.[2] This lack of target-mediated clearance pathway suggests that the target (IL-5Rα on eosinophils) is rapidly depleted, and the drug's elimination is primarily governed by the non-specific catabolic pathways of the reticuloendothelial system. The estimated systemic clearance (CL) for a 70 kg individual is 0.29 L/day. The elimination half-life is estimated to be approximately 15 to 18 days, which supports the extended maintenance dosing interval of every 8 weeks.[2]

5.0 Clinical Efficacy in Approved Indications

The regulatory approvals for Benralizumab are supported by a robust body of evidence from a comprehensive clinical trial program, demonstrating its efficacy in treating severe eosinophil-driven diseases.

5.1 Severe Eosinophilic Asthma (SEA)

The primary indication for Benralizumab is as an add-on maintenance therapy for patients with severe asthma characterized by an eosinophilic phenotype.

5.1.1 Analysis of the Pivotal WINDWARD Program

The foundational data for the initial approvals by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) came from the WINDWARD program, which consisted of three pivotal Phase III clinical trials.[8]

• SIROCCO (NCT01928771) and CALIMA (NCT01914757): These were large, randomized, double-blind, placebo-controlled trials designed to evaluate the effect of Benralizumab on the rate of asthma exacerbations. They enrolled patients with severe, uncontrolled asthma who were already on high-dose inhaled corticosteroids (ICS) plus a long-acting beta-agonist (LABA).[9]
• ZONDA (NCT02075255): This was a randomized, double-blind, placebo-controlled trial specifically designed to assess the oral corticosteroid (OCS)-sparing effect of Benralizumab in patients with severe asthma who were dependent on chronic OCS to manage their disease.[4]

The results from these trials were highly consistent and demonstrated significant clinical benefits across multiple key endpoints for the approved dosing regimen (30 mg every 4 weeks for 3 doses, then every 8 weeks). Key findings included [8]:

• Exacerbation Reduction: Benralizumab treatment led to a reduction of up to 51% in the annual asthma exacerbation rate (AAER) compared to placebo.
• Lung Function Improvement: Patients treated with Benralizumab showed a significant improvement in lung function, as measured by pre-bronchodilator forced expiratory volume in one second (FEV1​), with an increase of up to 159 mL compared to the placebo group. Notably, this improvement was observed as early as 4 weeks after the first dose, providing an early indication of efficacy.
• Oral Corticosteroid Sparing: In the ZONDA trial, patients receiving Benralizumab achieved a 75% median reduction in their daily OCS dose from baseline. Furthermore, 52% of eligible patients were able to completely discontinue their use of OCS, compared to a 25% median reduction in the placebo group.

Table 2: Summary of Key Efficacy Outcomes from Pivotal Phase III Asthma Trials (SIROCCO, CALIMA, ZONDA)

Trial	Patient Population	Endpoint	Result (Benralizumab vs. Placebo)	Source(s)
SIROCCO & CALIMA	Severe, uncontrolled asthma (ICS/LABA); Blood eosinophils ≥300 cells/μL	Annual Asthma Exacerbation Rate (AAER) Reduction	Up to 51% reduction vs. placebo	8
SIROCCO & CALIMA	Severe, uncontrolled asthma (ICS/LABA); Blood eosinophils ≥300 cells/μL	Change in pre-bronchodilator FEV1​	Up to +159 mL improvement vs. placebo	9
ZONDA	Severe, OCS-dependent asthma	Median % Reduction in Daily OCS Dose	75% reduction vs. 25% for placebo	4
ZONDA	Severe, OCS-dependent asthma	Proportion of Patients Discontinuing OCS	52% of eligible patients discontinued OCS	9
SIROCCO & CALIMA	Severe, uncontrolled asthma (ICS/LABA); Blood eosinophils ≥300 cells/μL	Change in Asthma Control Questionnaire (ACQ-6)	Statistically significant improvement vs. placebo	23
SIROCCO & CALIMA	Severe, uncontrolled asthma (ICS/LABA); Blood eosinophils ≥300 cells/μL	Change in Asthma Quality of Life Questionnaire (AQLQ(S)+12)	Statistically significant improvement vs. placebo	23

5.1.2 Efficacy in Pediatric and Adolescent Populations

The initial approval for Benralizumab was for patients aged 12 years and older.[8] Subsequent studies were conducted to establish its safety and efficacy in younger populations. The TATE study (NCT04305405), a Phase III open-label trial, evaluated the pharmacokinetics, pharmacodynamics, and long-term safety in children aged 6 to 11 with severe eosinophilic asthma.[28] These efforts led to the expansion of the indication to include this younger age group, with a weight-based dosing regimen.[22] It is worth noting that in the original pivotal trials, the treatment response observed in the adolescent subgroup (12 to 17 years) was numerically less than that seen in adults, although the trials were not statistically powered to detect a difference in this specific sub-population.[26]

5.1.3 Long-Term and Real-World Evidence

The benefits of Benralizumab have been shown to be durable over time. Data from the BORA trial, a long-term extension study for patients who completed the pivotal trials, demonstrated that the efficacy and safety profile were maintained for up to 43 months of continuous treatment.[23] Furthermore, a growing body of real-world evidence from observational studies and patient registries confirms that in routine clinical practice, treatment with Benralizumab is associated with significant and clinically meaningful improvements in asthma control, reductions in exacerbation rates, and improved lung function, with effect sizes that are comparable to those reported in the highly controlled environment of randomized controlled trials (RCTs).[31]

5.2 Eosinophilic Granulomatosis with Polyangiitis (EGPA)

EGPA, formerly known as Churg-Strauss Syndrome, is a rare, immune-mediated vasculitis characterized by severe asthma and profound eosinophilia, which can lead to life-threatening organ damage.[32] Benralizumab was approved for adult patients with EGPA in 2024.[7]

5.2.1 The MANDARA Trial (NCT04157348)

The approval for EGPA was based on the results of the MANDARA Phase III trial, a landmark study in the field.[7] This was the first trial to conduct a direct, head-to-head comparison of two biologics for EGPA. It was a multicenter, randomized, double-blind, non-inferiority trial that compared the efficacy and safety of Benralizumab to mepolizumab, which was the only other biologic approved for EGPA at the time.[7]

The trial successfully met its primary endpoint, demonstrating that Benralizumab was non-inferior to mepolizumab in the proportion of patients who were in remission at both week 36 and week 48. The results showed that nearly 60% of patients treated with Benralizumab achieved remission. Additionally, the trial highlighted a significant OCS-sparing effect, with 41% of patients on Benralizumab being able to completely stop their use of oral corticosteroids.[7]

The finding of non-inferiority between Benralizumab and mepolizumab is clinically significant, as it provides an alternative first-line biologic option for patients with EGPA. However, a deeper analysis of the trial design reveals a practical advantage that may influence treatment selection. The dosing regimen for Benralizumab in the MANDARA trial was a single 30 mg subcutaneous injection administered every 4 weeks.[23] In contrast, the regimen for the comparator, mepolizumab, consisted of three separate 100 mg subcutaneous injections administered every 4 weeks.[34] In the context of comparable clinical efficacy, the significantly lower injection burden of Benralizumab—a single monthly injection versus three—offers a substantial benefit in terms of patient convenience, reduced treatment administration time, and potentially improved long-term adherence. This practical difference is a key differentiator for clinicians and patients when choosing between these two effective therapies.

Table 3: Summary of Key Efficacy Outcomes from the MANDARA Phase III EGPA Trial

Endpoint	Description	Benralizumab Arm Result	Mepolizumab Arm Result	Statistical Conclusion	Source(s)
Primary Endpoint	Proportion of patients in remission* at Weeks 36 and 48	~60%	~60%	Benralizumab was non-inferior to mepolizumab	7
Key Secondary Endpoint	OCS Sparing	41% of patients fully stopped OCS use	Data not specified, but non-inferiority shown	Benralizumab helps patients taper off steroid therapy	7
Relapse	Time to first relapse	Non-inferior to mepolizumab	Non-inferior to Benralizumab	Comparable relapse prevention	7
Safety	Overall Adverse Event Profile	Consistent with the known profile of the medicine	Consistent with the known profile of the medicine	Similar safety and tolerability	7
*Remission was defined based on the Birmingham Vasculitis Activity Score (BVAS) and OCS dose.

6.0 Safety, Tolerability, and Risk Management

A thorough understanding of a drug's safety profile is paramount for its appropriate clinical use. The safety and tolerability of Benralizumab have been extensively evaluated in a large clinical development program and post-marketing surveillance.

6.1 Comprehensive Safety Profile

Across the pivotal Phase III trials for asthma, the overall adverse event profile of Benralizumab was found to be broadly similar to that of placebo.[9] The most commonly reported adverse reactions, occurring at an incidence of 5% or more in the US prescribing information, are headache and pharyngitis (sore throat).[21] In European summaries, headache was reported in 8% of asthma patients and 17% of EGPA patients, while pharyngitis was reported in 3% of asthma patients.[36] Injection site reactions, such as pain, erythema (redness), pruritus (itching), and papules, are also common but are typically mild and transient, occurring in approximately 2.2% of patients treated with Benralizumab compared to 1.9% in patients treated with placebo.[23] Importantly, large clinical trials did not find an increased rate of serum aminotransferase or alkaline phosphatase elevations, and there have been no published reports of clinically apparent drug-induced liver injury attributed to Benralizumab.[19]

6.2 Contraindications, Warnings, and Precautions for Use

Regulatory agencies have established specific contraindications and a set of warnings and precautions to guide the safe use of Benralizumab.

6.2.1 Contraindication

The sole absolute contraindication for Benralizumab is a known hypersensitivity to the active substance (benralizumab) or to any of its excipients.[21]

6.2.2 Warnings and Precautions

A number of important warnings and precautions are listed in the official prescribing information to mitigate potential risks:

• Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis, angioedema, urticaria (hives), and rash, have been reported following the administration of Benralizumab. These reactions can be immediate, occurring within hours of administration, but in some instances have a delayed onset of several days. A history of anaphylaxis unrelated to Benralizumab may be a risk factor. In the event of a hypersensitivity reaction, Benralizumab should be discontinued permanently and appropriate medical treatment initiated.[19]
• Acute Asthma Symptoms or Deteriorating Disease: Benralizumab is a maintenance therapy and should not be used for the treatment of acute asthma symptoms, acute exacerbations, acute bronchospasm, or status asthmaticus. Patients should be instructed to seek medical advice if their asthma remains uncontrolled or worsens after starting treatment.[21]
• Reduction of Corticosteroid Dosage: Systemic or inhaled corticosteroids should not be discontinued abruptly upon initiation of Benralizumab therapy. If a reduction in corticosteroid dose is deemed appropriate, it should be done gradually and under the direct supervision of a physician. Rapid dose reduction may be associated with systemic withdrawal symptoms or may unmask underlying conditions (e.g., EGPA) that were previously suppressed by the systemic corticosteroid therapy.[21]
• Parasitic (Helminth) Infection: Eosinophils play a role in the immunological response to some helminth (worm) infections. It is unknown if Benralizumab will influence a patient's ability to fight these infections. Therefore, patients with pre-existing helminth infections should be treated for the infection before initiating therapy with Benralizumab. If a patient becomes infected while receiving the drug and does not respond to anti-helminth treatment, Benralizumab should be discontinued until the infection resolves.[4]

Table 4: Comprehensive Safety Information: Contraindications, Warnings, and Common Adverse Reactions

Category	Description	Source(s)
Contraindication	Known hypersensitivity to benralizumab or any of its excipients.	21
Warnings & Precautions	Hypersensitivity Reactions: Anaphylaxis, angioedema, urticaria, and rash have occurred. Reactions can be immediate (hours) or delayed (days). Discontinue if a reaction occurs.	21
	Acute Asthma Symptoms: Not for treatment of acute bronchospasm or status asthmaticus. It is a maintenance therapy.	21
	Corticosteroid Reduction: Do not discontinue corticosteroids abruptly. Taper gradually under medical supervision to avoid withdrawal or unmasking of underlying conditions.	21
	Parasitic (Helminth) Infection: Treat pre-existing helminth infections before starting. If infection occurs during treatment and is unresponsive to anti-helminth therapy, discontinue benralizumab until resolved.	21
Adverse Reactions (Common)	Headache: Reported in ≥5% of patients in US trials and 8-17% in EU summaries.	21
	Pharyngitis (Sore Throat): Reported in ≥5% of patients in US trials and 3% in EU summaries.	21
	Injection Site Reactions: Pain, erythema, pruritus, papule. Occurred in 2.2% of patients vs. 1.9% for placebo. Typically transient.	23
	Pyrexia (Fever): Listed as a common adverse reaction.	37

6.3 Immunogenicity

As with all therapeutic proteins, there is a potential for immunogenicity. In the pivotal asthma trials, anti-drug antibodies (ADAs) to Benralizumab were detected in approximately 13% of patients treated with the recommended dosing regimen over a 48 to 56-week period.[4] In a majority of these cases, the ADAs were found to be neutralizing

in vitro. The summary analysis concluded that there was no apparent correlation between the development of ADAs and overall treatment efficacy or the incidence of adverse effects in the study population as a whole.[4]

However, a more detailed examination of the data reveals a clinically important nuance. While ADA development may not impact the average patient, it was observed that patients who developed high titers of ADAs were associated with increased clearance of Benralizumab from their system and, consequently, increased blood eosinophil levels.[4] This finding suggests that while immunogenicity is not a widespread clinical problem, it can be the specific, underlying mechanism of treatment failure in a subset of individuals. For a clinician managing a patient who initially responded to Benralizumab but later experiences a loss of efficacy, the development of high-titer neutralizing antibodies represents a valid and mechanistically plausible explanation that should be considered.

6.4 Use in Special Populations

• Pregnancy: There is a limited amount of data (fewer than 300 pregnancy outcomes) on the use of Benralizumab in pregnant women. As an IgG monoclonal antibody, Benralizumab is actively transported across the placenta, particularly during the second and third trimesters, leading to potential fetal exposure. As a precautionary measure, its use during pregnancy should only be considered if the expected benefit to the mother outweighs any possible risk to the fetus. A pregnancy exposure registry has been established to monitor outcomes in women exposed to the drug during pregnancy.[35]
• Lactation: It is currently unknown whether Benralizumab or its metabolites are excreted in human milk. A decision must be made on a case-by-case basis whether to discontinue breastfeeding or to discontinue/abstain from Benralizumab therapy, taking into account the benefit of breastfeeding for the child and the benefit of the therapy for the woman.[36]
• Hepatic and Renal Impairment: Population pharmacokinetic analyses indicate that hepatic or renal function does not have a clinically significant impact on Benralizumab clearance. Therefore, no dose adjustment is required for patients with renal or hepatic impairment.[23]

7.0 Drug Interaction Profile

The potential for drug-drug interactions is a critical consideration in clinical practice, especially for patients with complex, multi-morbid conditions who are often on numerous medications.

7.1 Pharmacokinetic Interactions

Benralizumab is a monoclonal antibody, and its metabolism and clearance pathways differ fundamentally from those of small-molecule drugs. It is cleared from the body via catabolism through the action of proteolytic enzymes that are ubiquitous and not localized to a specific organ like the liver.[2] It is not a substrate, inhibitor, or inducer of the cytochrome P450 (CYP) enzyme system, which is responsible for the metabolism of a vast number of common drugs. Consequently, Benralizumab is not expected to have any clinically relevant pharmacokinetic interactions with drugs that are metabolized by CYP enzymes. Formal drug-drug interaction studies have not been conducted.

7.2 Pharmacodynamic Interactions

While pharmacokinetic interactions are unlikely, pharmacodynamic interactions are a theoretical consideration. The DrugBank database lists a large number of other monoclonal antibodies where the "risk or severity of adverse effects can be increased when...combined with Benralizumab".[2] This is a general, class-based warning that applies to the combination of multiple immunomodulatory biologics. It reflects a theoretical risk of cumulative immunosuppression or other unforeseen effects on the immune system, rather than specific, documented clinical interactions for each individual drug pairing.

The only specific disease interaction noted is with "infections".[40] This is not an interaction with another drug, but rather a reflection of the drug's mechanism of action and is directly related to the formal warning regarding parasitic (helminth) infections. Because eosinophils are part of the innate immune response to these parasites, a drug that depletes eosinophils could potentially alter a patient's ability to control such an infection.

8.0 Comparative Analysis with Other Biologics for Type 2 Inflammation

The therapeutic landscape for severe asthma has been transformed by the introduction of several targeted biologic therapies. Placing Benralizumab in context with its main competitors—mepolizumab, reslizumab, and dupilumab—requires a comparison of their distinct mechanisms, relative efficacy, and safety profiles.

8.1 Mechanistic Distinctions

The key biologics for T2-high asthma can be differentiated by their specific molecular targets within the inflammatory cascade.

• Benralizumab (Fasenra): Uniquely targets the IL-5 receptor alpha (IL-5Rα) subunit on the surface of eosinophils and basophils. Its primary mechanism is the induction of direct cell death via enhanced ADCC, supplemented by blockade of IL-5 signaling.[5]
• Mepolizumab (Nucala) & Reslizumab (Cinqair/Cinqaero): These two antibodies target the IL-5 ligand itself. They bind to circulating IL-5, sequestering it and preventing it from interacting with its receptor on eosinophils. This leads to a reduction in eosinophil production and survival by blocking the pro-survival signal, but it does not involve active cell killing.[41]
• Dupilumab (Dupixent): This antibody targets a different part of the T2 pathway. It binds to the IL-4 receptor alpha (IL-4Rα) subunit, which is a shared component of the receptor complexes for both IL-4 and IL-13. By blocking this shared receptor component, Dupilumab simultaneously inhibits the signaling of two key upstream cytokines that drive multiple aspects of T2 inflammation, including IgE production, mucus hypersecretion, and airway hyperreactivity.[47]

8.2 Comparative Efficacy and Safety

Direct head-to-head comparative trials between all these biologics for severe asthma are largely absent, making systematic reviews and network meta-analyses the primary source for comparative evidence.[50]

• Efficacy: These analyses consistently show that all four biologics (benralizumab, mepolizumab, reslizumab, and dupilumab) provide significant benefits over standard of care. There is high-certainty evidence that all of them effectively reduce the rate of severe asthma exacerbations.[51] There is also high-certainty evidence that benralizumab, mepolizumab, and dupilumab are effective at reducing the need for oral corticosteroids. All of the biologics likely improve measures of asthma control (e.g., ACQ score) and lung function ( FEV1​), although the magnitude of this improvement often does not reach the pre-defined minimal important difference (MID) in meta-analyses.[51]
• Safety: In terms of safety, systematic reviews suggest that benralizumab, mepolizumab, and reslizumab may be associated with a slight increase in drug-related adverse events compared to placebo (low to moderate certainty). The risk with dupilumab and omalizumab appears to be smaller. The evidence regarding drug-related serious adverse events is generally of low to very low certainty, with inconclusive results for most agents.[51] More long-term safety data are needed for the newer biologics, including Benralizumab.[51]

Table 5: Comparative Overview of Biologics for Severe Eosinophilic Asthma

Biologic (Brand Name)	Molecular Target	Core Mechanism	Maintenance Dosing Frequency	Key Differentiator
Benralizumab (Fasenra)	IL-5 Receptor α (IL-5Rα)	Direct eosinophil killing via ADCC & receptor blockade	Every 8 weeks (Asthma)	Actively depletes existing eosinophils; rapid onset
Mepolizumab (Nucala)	IL-5 Ligand	Sequesters circulating IL-5, preventing receptor binding	Every 4 weeks	Blocks IL-5 signaling, reducing eosinophil production/survival
Reslizumab (Cinqair)	IL-5 Ligand	Sequesters circulating IL-5, preventing receptor binding	Every 4 weeks (IV infusion)	IV administration; targets IL-5 ligand
Dupilumab (Dupixent)	IL-4 Receptor α (IL-4Rα)	Blocks signaling of both IL-4 and IL-13	Every 2 weeks	Broader T2 inflammation blockade (IL-4/IL-13 pathways)

9.0 Investigational Uses and Future Directions

Benralizumab's potent and specific eosinophil-depleting activity makes it an attractive candidate for a range of eosinophil-driven diseases beyond its approved indications. Its investigation in these areas has yielded both promising results and critical scientific insights.

9.1 Eosinophilic Esophagitis (EoE): The Implications of the MESSINA Trial's Histologic-Symptomatic Discordance

In August 2019, the FDA granted Benralizumab an Orphan Drug Designation for the treatment of eosinophilic esophagitis (EoE), a chronic allergic inflammatory disease of the esophagus.[1] This designation paved the way for the pivotal Phase 3 MESSINA trial (NCT04543409), which was designed to evaluate its efficacy and safety in adolescent and adult patients with symptomatic and histologically active EoE.[15]

The results of the MESSINA trial were striking and have had a profound impact on the understanding of EoE. The trial successfully met one of its two dual-primary endpoints: Benralizumab demonstrated a superior rate of histologic response. At week 24, 87.4% of patients in the Benralizumab group achieved the target of having ≤6 eosinophils per high-power field in their esophageal tissue, compared to only 6.5% of patients in the placebo group—a highly statistically significant difference.[15] This confirmed that the drug was highly effective at clearing eosinophils from the target organ.

However, the trial failed to meet its other co-primary endpoint. Despite the profound histologic improvement, there was no significant difference in the change from baseline in dysphagia (difficulty swallowing) symptoms between the Benralizumab and placebo groups.[15] Due to this lack of clear clinical benefit on the primary symptom of the disease, AstraZeneca terminated the study and its development program for Benralizumab in EoE.[16]

The outcome of the MESSINA trial, while a "failure" from a drug development perspective, represents a pivotal scientific experiment for the field of gastroenterology. For years, the prevailing hypothesis in EoE was that eosinophils were the direct cause of the esophageal dysfunction and symptoms like dysphagia. Benralizumab provided the perfect biological tool to test this hypothesis, as it allowed for the potent and specific removal of eosinophils from the equation. The fact that eosinophil depletion did not lead to symptomatic improvement strongly challenges this simple, linear model of pathophysiology. It suggests that while eosinophils may be critical in initiating and perpetuating the inflammatory cascade, they are not the sole or even the primary drivers of persistent symptoms like dysphagia in patients with established disease. The trial's results point toward the importance of other downstream or parallel pathological processes, such as mast cell activation, chronic tissue remodeling, fibrosis, and neuromuscular dysfunction, as the more proximate causes of clinical symptoms. Thus, the MESSINA trial has reshaped the scientific understanding of EoE and will undoubtedly guide future therapeutic development toward these alternative targets.

9.2 Hypereosinophilic Syndrome (HES)

HES is a group of rare and potentially fatal disorders characterized by persistently elevated eosinophil counts leading to organ damage.[54] Benralizumab is being actively investigated for the treatment of patients with HES who are negative for the

FIP1L1-PDGFRA fusion gene.[13]

A Phase II trial (NCT02130882), conducted in collaboration with the US National Institute of Allergy and Infectious Diseases (NIAID), provided strong proof-of-concept.[54] In this 20-patient, placebo-controlled study, 90% of patients treated with Benralizumab achieved a 50% or greater reduction in their blood eosinophil counts at week 12, compared to just 30% of patients on placebo. In the subsequent open-label extension phase, 74% of patients maintained their response, and importantly, 64% were able to successfully taper their background HES medications, such as corticosteroids.[54] Remarkably, long-term follow-up data from this cohort, with some patients receiving treatment for over 8 years (maximum 10.1 years), have shown that Benralizumab therapy is effective and well-tolerated over the long term, with sustained eosinophil suppression and a favorable safety profile.[13]

These encouraging Phase II results have led to a larger, ongoing Phase III study, NATRON (NCT04191304), which is designed to further evaluate the efficacy and safety of Benralizumab in a broader HES population.[14] The long-term data from the Phase II extension have also provided valuable clinical insights, notably that most HES patients required sustained monthly dosing to control their symptoms and eosinophil counts, in contrast to the every-8-week maintenance schedule used in asthma. This suggests that the "eosinophilic burden" in HES is substantially higher and requires more intensive and continuous suppression.[13]

9.3 Other Emerging Therapeutic Targets

The potent eosinophil-depleting properties of Benralizumab have prompted investigation in other related conditions.

• Chronic Obstructive Pulmonary Disease (COPD): Early trials in COPD patients with sputum eosinophilia showed that while Benralizumab effectively depleted eosinophils, it did not lead to a statistically significant reduction in the rate of acute exacerbations compared to placebo.[19] More recent research from the ABRA study has explored a different strategy, suggesting that a single dose of Benralizumab administered at the onset of an exacerbation might be more effective than the standard treatment with oral steroid tablets in high-risk patients.[1]
• Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): This condition, often co-existing with severe asthma, is characterized by eosinophilic inflammation in the sinuses. It is listed as a disease for which Benralizumab is in development.[7]
• Other Rare Eosinophilic Diseases: Case reports have documented the successful off-label use of Benralizumab in treating individual patients with severe, refractory conditions such as non-necrotizing eosinophilic vasculitis and Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome, suggesting its potential as a life-saving therapy when conventional treatments have failed.[57]

10.0 Regulatory and Administrative Synopsis

The journey of Benralizumab from a developmental compound to a globally approved therapeutic has been marked by a series of key regulatory milestones and is defined by specific guidelines for its administration.

10.1 Global Regulatory History and Approval Timelines

Benralizumab was developed by MedImmune, the global biologics research and development arm of AstraZeneca, which now markets the drug worldwide.[1] It is in-licensed from BioWa, Inc., a subsidiary of Kyowa Hakko Kirin.[25]

• U.S. Food and Drug Administration (FDA):
• November 14, 2017: Initial approval for the add-on maintenance treatment of severe eosinophilic asthma in patients aged 12 years and older.[1]
• August 28, 2019: Granted Orphan Drug Designation for the treatment of eosinophilic esophagitis (EoE).[1]
• October 4, 2019: Approval of the Fasenra Pen™, a pre-filled auto-injector for self-administration.[29]
• April 11, 2024: Approval expanded to include children aged 6 to 11 with severe eosinophilic asthma.[29]
• September 18, 2024: Approved for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).[7]
• European Medicines Agency (EMA):
• January 8, 2018: Granted marketing authorisation for the add-on maintenance treatment of adult patients with severe eosinophilic asthma.[25]
• October 2024: Approval expanded to include the treatment of adult patients with relapsing or refractory EGPA.[33]

In addition to the US and EU, Benralizumab is approved for use in over 80 countries, including Japan and China, and has been prescribed to over 130,000 patients globally.[7]

Table 6: Global Regulatory Approval Milestones

Date	Regulatory Agency	Action	Indication / Patient Population	Source(s)
Nov 14, 2017	FDA (US)	Approval	Severe Eosinophilic Asthma (≥12 years)	1
Jan 8, 2018	EMA (EU)	Approval	Severe Eosinophilic Asthma (Adults)	25
Aug 28, 2019	FDA (US)	Orphan Drug Designation	Eosinophilic Esophagitis (EoE)	1
Oct 4, 2019	FDA (US)	Approval	Fasenra Pen™ (auto-injector)	29
Apr 11, 2024	FDA (US)	Approval	Severe Eosinophilic Asthma (6-11 years)	29
Sep 18, 2024	FDA (US)	Approval	Eosinophilic Granulomatosis with Polyangiitis (EGPA) (Adults)	7
Oct 2024	EMA (EU)	Approval	Eosinophilic Granulomatosis with Polyangiitis (EGPA) (Adults)	33

10.2 Dosing, Formulation, and Administration

• Formulation: Benralizumab is available as a 30 mg solution for injection in a single-use pre-filled syringe or a single-use pre-filled auto-injector, known as the Fasenra Pen™.[29]
• Administration: The drug is administered via subcutaneous injection. Recommended injection sites are the thigh or abdomen. The upper arm can also be used if the injection is given by a healthcare professional or caregiver.[23] After proper training on the injection technique and on recognizing the signs of a hypersensitivity reaction, patients or their caregivers may self-administer the drug.[23]
• Dosing Regimen: The recommended dose varies by indication and patient age/weight.
• Severe Eosinophilic Asthma (Adults and Adolescents ≥12 years): The regimen starts with a loading phase of 30 mg administered once every 4 weeks for the first three doses. This is followed by a maintenance phase of 30 mg administered once every 8 weeks thereafter.[8]
• Severe Eosinophilic Asthma (Children 6-11 years): The dosing is weight-based. For children weighing 35 kg or more, the dose is 30 mg. For children weighing less than 35 kg, the dose is 10 mg. The schedule is the same as for adults: every 4 weeks for the first three doses, then every 8 weeks.[22]
• Eosinophilic Granulomatosis with Polyangiitis (Adults): The recommended dose is 30 mg administered once every 4 weeks.[7]

11.0 Conclusion and Expert Insights

Benralizumab (Fasenra) has firmly established itself as a cornerstone therapy in the management of severe eosinophil-driven diseases. Its development and clinical application represent a triumph of rational drug design, translating a deep understanding of molecular immunology into a highly effective and well-tolerated therapeutic agent.

The defining feature of Benralizumab is its unique, dual-action mechanism. By targeting the IL-5 receptor alpha subunit directly on the surface of eosinophils, it not only blocks pro-survival signaling but, more importantly, leverages the power of the innate immune system to induce rapid and profound cell death via antibody-dependent cell-mediated cytotoxicity (ADCC). This mechanism, potentiated by the deliberate afucosylation of the antibody's Fc region, is responsible for the near-complete and sustained depletion of eosinophils from blood and tissues—a pharmacodynamic effect that is more rapid and deep than that achieved by ligand-sequestering antibodies.

In the clinical arena, this potent biological activity has translated into robust efficacy. For patients with severe eosinophilic asthma, Benralizumab has demonstrated significant reductions in exacerbation rates, improvements in lung function, and a remarkable ability to reduce or eliminate the need for chronic oral corticosteroids, a class of drugs fraught with long-term toxicities. In the rare and challenging disease of EGPA, it has proven to be non-inferior to the existing standard of biologic care, while offering a significantly more convenient single-injection monthly dosing regimen that reduces treatment burden for patients.

Perhaps just as significant as its therapeutic successes are the scientific insights gleaned from its investigational use. The study of Benralizumab in HES has provided valuable long-term data on the management of diseases with extreme eosinophilic load. Most profoundly, the "failed" MESSINA trial in eosinophilic esophagitis has become a landmark experiment. By successfully decoupling histologic eosinophil clearance from symptomatic improvement, the trial has fundamentally challenged and refined the scientific community's understanding of EoE pathophysiology. It demonstrated that Benralizumab is not just a therapeutic drug, but also a precision biological tool capable of dissecting complex disease mechanisms in vivo.

In conclusion, Benralizumab is a highly differentiated biologic therapy that has transformed the treatment paradigm for thousands of patients with severe eosinophilic asthma and EGPA. Its unique mechanism provides a distinct clinical profile, and its continued study promises not only to expand its therapeutic applications but also to further illuminate the complex and multifaceted role of the eosinophil in human health and disease.

Works cited

1. Benralizumab - Wikipedia, accessed August 1, 2025, https://en.wikipedia.org/wiki/Benralizumab
2. Benralizumab: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed August 1, 2025, https://go.drugbank.com/drugs/DB12023
3. Benralizumab (Anti-IL-5Ra/ CD125) IL Receptor antibody | Read Reviews & Product Use Citations - Selleckchem.com, accessed August 1, 2025, https://www.selleckchem.com/products/benralizumab-anti-il-5ra-cd125.html
4. Clinical Recommendations For The Use Of Benralizumab In Severe Asthma, accessed August 1, 2025, https://www.severeasthma.org.au/benralizumab/
5. Benralizumab in the treatment of severe asthma: design, development an | DDDT, accessed August 1, 2025, https://www.dovepress.com/benralizumab-in-the-treatment-of-severe-asthma-design-development-and--peer-reviewed-fulltext-article-DDDT
6. Benralizumab - brand name list from Drugs.com, accessed August 1, 2025, https://www.drugs.com/ingredient/benralizumab.html
7. FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis, accessed August 1, 2025, https://www.astrazeneca-us.com/media/press-releases/2024/fasenra-approved-in-the-us-for-eosinophilic-granulomatosis-with-polyangiitis.html
8. FASENRA (benralizumab) Receives US FDA Approval For Severe Eosinophilic Asthma, accessed August 1, 2025, https://www.prnewswire.com/news-releases/fasenra-benralizumab-receives-us-fda-approval-for-severe-eosinophilic-asthma-300556129.html
9. Fasenra (benralizumab) receives US FDA approval for severe ..., accessed August 1, 2025, https://www.astrazeneca.com/media-centre/press-releases/2017/fasenra-benralizumab-receives-us-fda-approval-for-severe-uncontrolled-eosinophilic-asthma-14112017.html
10. What is Fasenra used for and how does it work? - Drugs.com, accessed August 1, 2025, https://www.drugs.com/medical-answers/fasenra-work-3541067/
11. Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity, accessed August 1, 2025, https://publications.ersnet.org/content/erj/59/3/2004306
12. Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity, accessed August 1, 2025, https://pubmed.ncbi.nlm.nih.gov/34289975/
13. Long-Term Efficacy and Safety of Benralizumab Treatment for PDGFRA-Negative Hypereosinophilic Syndrome - PubMed, accessed August 1, 2025, https://pubmed.ncbi.nlm.nih.gov/40120806/
14. A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) (NATRON) - ClinicalTrials.gov, accessed August 1, 2025, https://clinicaltrials.gov/study/NCT04191304
15. Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis | Amsterdam UMC, accessed August 1, 2025, https://pure.amsterdamumc.nl/files/142442646/Eosinophil-depletion-with-benralizumab-for-eosinophilic-esophagitis.pdf
16. Study Details | A Study of Benralizumab in Patients With ..., accessed August 1, 2025, https://www.clinicaltrials.gov/study/NCT04543409
17. Benralizumab | Apoptosis | Interleukin | IL Receptor - TargetMol, accessed August 1, 2025, https://www.targetmol.com/compound/benralizumab
18. Benralizumab CAS#: 1044511-01-4 - ChemicalBook, accessed August 1, 2025, https://amp.chemicalbook.com/ProductChemicalPropertiesCB55821388_EN.htm
19. Benralizumab - LiverTox - NCBI Bookshelf, accessed August 1, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548640/
20. Benralizumab (MEDI-563) | anti-IL-5Rα mAb - MedchemExpress.com, accessed August 1, 2025, https://www.medchemexpress.com/benralizumab.html
21. Fasenra: Package Insert / Prescribing Information - Drugs.com, accessed August 1, 2025, https://www.drugs.com/pro/fasenra.html
22. Benralizumab (subcutaneous route) - Side effects & dosage - Mayo Clinic, accessed August 1, 2025, https://www.mayoclinic.org/drugs-supplements/benralizumab-subcutaneous-route/description/drg-20406682
23. Fasenra, INN-benralizumab - European Medicines Agency, accessed August 1, 2025, https://www.ema.europa.eu/en/documents/product-information/fasenra-epar-product-information_en.pdf
24. FASENRA® (benralizumab) Mechanism of Action | For HCPs, accessed August 1, 2025, https://www.fasenrahcp.com/mechanism-of-action
25. AstraZeneca receives EU approval of Fasenra for severe eosinophilic asthma, accessed August 1, 2025, https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-receives-eu-approval-of-fasenra-for-severe-eosinophilic-asthma-10012018.html
26. Fasenra prefilled syringe and Fasenra pen - NPS MedicineWise, accessed August 1, 2025, https://www.nps.org.au/medicine-finder/fasenra
27. Benralizumab Completed Phase 3 Trials for Asthma Treatment | DrugBank Online, accessed August 1, 2025, https://go.drugbank.com/drugs/DB12023/clinical_trials?conditions=DBCOND0013565&phase=3&purpose=treatment&status=completed
28. PK/​PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma (TATE) - ClinicalTrials.gov, accessed August 1, 2025, https://clinicaltrials.gov/study/NCT04305405
29. Fasenra (benralizumab) FDA Approval History - Drugs.com, accessed August 1, 2025, https://www.drugs.com/history/fasenra.html
30. FASENRA® (benralizumab) for Severe Eosinophilic Asthma | For ..., accessed August 1, 2025, https://www.fasenrahcp.com/
31. Real‐world efficacy of treatment with benralizumab, dupilumab ..., accessed August 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9311192/
32. Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis - AstraZeneca, accessed August 1, 2025, https://www.astrazeneca.com/media-centre/press-releases/2024/fasenra-approved-in-the-us-for-eosinophilic-granulomatosis-with-polyangiitis.html
33. AstraZeneca's Fasenra Approved in EU for EGPA - EOS Network, accessed August 1, 2025, https://www.eosnetwork.org/news/fasenra-approved-in-eu-for-egpa
34. Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis - AstraZeneca, accessed August 1, 2025, https://www.astrazeneca.com/media-centre/press-releases/2024/fasenra-approved-in-the-eu-for-eosinophilic-granulomatosis-with-polyangiitis.html
35. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Known hypersensitivity to benralizumab or excipients. WARNINGS AND PRECAUTIONS Hy - FASENRA Studies in Severe Asthma, accessed August 1, 2025, https://www.fasenrastudies.com/content/dam/open-digital/fasenra-medical/en/pdf/phase2/FASENRA_ZEPHYR_2_Study_Poster_CHEST_PEDS_UPDATE_2024.pdf
36. This medicinal product is subject to additional monitoring. This will allow quick identification of - Fasenra, INN-benralizumab, accessed August 1, 2025, https://ec.europa.eu/health/documents/community-register/2018/20180108139598/anx_139598_en.pdf
37. Fasenra 30 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc) | 8918, accessed August 1, 2025, https://www.medicines.org.uk/emc/product/8918/smpc
38. Fasenra | European Medicines Agency (EMA), accessed August 1, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/fasenra
39. Welcome to FASENRA 360 support with emails and more, accessed August 1, 2025, https://www.fasenra.com/sign-up
40. Benralizumab Interactions Checker - Drugs.com, accessed August 1, 2025, https://www.drugs.com/drug-interactions/benralizumab.html
41. target eosinophils in severe asthma with anti-il-5 therapy - Nucala HCP, accessed August 1, 2025, https://nucalahcp.com/severe-eosinophilic-asthma/eosinophils-moa/
42. nucalahcp.com, accessed August 1, 2025, https://nucalahcp.com/severe-eosinophilic-asthma/eosinophils-moa/#:~:text=affinity%20and%20specificity.-,The%20mechanism%20of%20action%20of%20mepolizumab,has%20not%20been%20definitively%20established.&text=IL%2D5R%20alpha-,WOMAN%20NARRATOR%3A,production%20and%20survival%20of%20eosinophils.
43. Clinical Recommendations for Use of Mepolizumab in Severe Asthma, accessed August 1, 2025, https://www.severeasthma.org.au/mepolizumab/
44. What is the mechanism of Mepolizumab? - Patsnap Synapse, accessed August 1, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-mepolizumab
45. AusPAR - CINQAIR / CINQAERO - Reslizumab - Teva Pharma Australia Pty Ltd - Therapeutic Goods Administration (TGA), accessed August 1, 2025, https://www.tga.gov.au/sites/default/files/auspar-reslizumab-180605-pi.pdf
46. Reslizumab - Wikipedia, accessed August 1, 2025, https://en.wikipedia.org/wiki/Reslizumab
47. pmc.ncbi.nlm.nih.gov, accessed August 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11288895/#:~:text=Mechanism%20of%20action%3A%20Inhibition%20of,%2C%20eosinophilic%20esophagitis%2C%20prurigo%20nodularis.
48. Dupilumab: Mechanism of action, clinical, and translational science, accessed August 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11288895/
49. The Role of Dupilumab in Severe Asthma - MDPI, accessed August 1, 2025, https://www.mdpi.com/2227-9059/9/9/1096
50. Efficacy comparison of biologics (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) in treatment of severe eosinophilic asthma — a network meta-analysis - Vivli, accessed August 1, 2025, https://vivli.org/efficacy-comparison-of-biologics-benralizumab-dupilumab-mepolizumab-omalizumab-and-reslizumab-in-treatment-of-severe-eosinophilic-asthma-a-network-meta-analysis/
51. Efficacy and safety of treatment with biologicals (benralizumab ... - IRIS, accessed August 1, 2025, https://iris.unife.it/retrieve/e309ade4-c029-3969-e053-3a05fe0a2c94/all.14221.pdf
52. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - ResearchGate, accessed August 1, 2025, https://www.researchgate.net/publication/348400447_Efficacy_and_safety_of_treatment_with_biologicals_benralizumab_dupilumab_mepolizumab_omalizumab_and_reslizumab_for_severe_eosinophilic_asthma_A_systematic_review_for_the_EAACI_Guidelines_-_recommendat
53. Benralizumab associated with histologic response in eosinophilic esophagitis, accessed August 1, 2025, https://www.2minutemedicine.com/benralizumab-associated-with-histologic-response-in-eosinophilic-esophagitis/
54. Positive results from Fasenra Phase II trial in hypereosinophilic ..., accessed August 1, 2025, https://www.astrazeneca.com/media-centre/press-releases/2019/positive-results-from-fasenra-phase-ii-trial-in-hypereosinophilic-syndrome-published-in-new-england-journal-of-medicine-04042019.html
55. Haematological disorders Unknown Status Phase 2 / 3 Trials for Benralizumab (DB12023), accessed August 1, 2025, https://go.drugbank.com/indications/DBCOND0026456/clinical_trials/DB12023?phase=2%2C3&status=unknown_status
56. Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome | ClinicalTrials.gov, accessed August 1, 2025, https://clinicaltrials.gov/study/NCT02130882
57. Off-Label Benralizumab in Severe Non-Necrotizing Eosinophilic Vasculitis following Critical COVID-19 Disease and in DRESS - MDPI, accessed August 1, 2025, https://www.mdpi.com/2077-0383/11/22/6642